Home
NICE Guidance
Published Guidance

Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence

Technology appraisal guidance [TA553] Published: 19 December 2018

Guidance

This guidance has been updated and replaced by NICE technology appraisal guidance 766.